The Bioconjugates Stream at 
PEGS - The Essential Protein Engineering Summit 
Preliminary Agenda Announcement

Bioconjugates as Therapeutics: from R&D to Clinical Development
The Bioconjugation Stream brings together 2 promising and exciting proteins in the category – Fusion Proteins and Antibody-Drug Conjugates - and explores their current and future prospects as therapeutics. The Fusion Protein Therapeutics conference explores the varying constructs of fusion protein molecules to deliver higher efficacy, greater specificity and longer half-lives. The Antibody-Drug Conjugates I conference underlies the industry’s greater understanding of ADC chemistry and biology, prompting creative design and engineering of next-generation linkers, payloads and antibodies; while Antibody-Drug Conjugates II invites scientists to share their latest clinical results and lessons learned to help advance their molecules and drive clinical success.

CONFERENCES INCLUDE:

3^rd Annual
Fusion Protein Therapeutics
Engineering Next-Generation Biologics

» View the preliminary agenda

The customizable functionality of Fusion Protein Therapeutics creates advantages over antibody-based therapies by combining modular building blocks that can reach targets not accessible to antibodies. Additional advantages include lower patient dosing, reduced production costs, and improved product homogeneity. The Fusion Protein Therapeutics conference explores the varying constructs and ‘designs’ of fusion protein molecules, and will disclose how they are being engineered to form more efficacious therapeutics that offer specificity with enhanced stability and longer half-life. Experts will present case studies from R&D through clinical data, and will share the results they’ve achieved.

KEYNOTE PRESENTATION:

From Cytokine Traps to Antibody-Based Protein Therapeutics: A Scientific Journey
Aris N. Economides, Ph.D., Executive Director; Genome Engineering Technologies, and Skeletal Diseases TFA, Co-Founder & Head of Functional Modeling; Regeneron Genetics Center, Regeneron Pharmaceuticals, Inc.

SESSION TOPICS:

·         The Promise of Fusion Proteins

·         Engineering Innovations

·         Conquering Disease

·         TRAIL: Tumor Necrosis Factor-related Apoptosis-Inducing Ligand

7^th Annual
Antibody-Drug Conjugates I: New Targets, Payloads and Alternative Formats
Innovative Engineering and Creative Chemistry to Optimize Therapeutic Impact

» View the preliminary agenda

Lessons learned from the two marketed ADCs and the ongoing ADC trials have not only enabled scientists to better understand the mechanisms of action of antibody-drug conjugates, but also helped invigorate a new field of ADC study aimed at overcoming the challenges of poor internalization, tumor non-specificity, off-target toxicity, lack of efficacy, low expression levels and multi-drug resistance. Today, scientists continue to innovate on next generation ADCs by improving target selection, finding new cytotoxic drugs as warheads, engineering antibodies or discovering alternative effector moieties to increase half-lives and improve target specificity, optimizing linker-payload chemistry to produce stable and homogeneous ADCs, and overcoming the challenges of multi-drug resistance.

SESSION TOPICS:

·         Novel Payloads

·         Alternative Formats And Effector Moities

·         Optimizing Linked and Conjugation Chemistry

7^th Annual
Antibody-Drug Conjugates II: Advancing Toward the Clinic
Lessons Learned from Preclinical and Early Trials to Drive Clinical Success

» View the preliminary agenda

This is an exciting time for antibody-drug conjugate developers. With many ADCs moving into later-stage clinical trials, the industry is eagerly anticipating the results from these trials. Some of the lessons learned from earlier trials have already been applied to new generations of ADC design, helping the industry to overcome the setbacks previously experienced. The industry is now eagerly anticipating data from new pivotal trials in solid tumors, results from trials with new payloads and linkers, and outcomes from combination therapies.

KEYNOTE PRESENTATION:

Leveraging Antibody-Drug Conjugates to Eradicate Tumor-Initiating Cells
Scott J. Dylla, Ph.D., Vice President, Research & Development, CSO, AbbVie Stemcentrx, LLC

SESSION TOPICS:

·         Preclinical Data to Update Clinical Studies

·         Clinical Updates